clindamycin phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3909 24729-96-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clindamycin phosphate
  • cleocin phosphate
  • clindagel
  • clindamycin-2-phosphate
  • Molecular weight: 504.96
  • Formula: C18H34ClN2O8PS
  • CLOGP: -1.17
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 5
  • TPSA: 148.79
  • ALOGS: -2.21
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 2, 1972 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1836.41 10.39 1370 28847 249640 50325267
Acute generalised exanthematous pustulosis 249.78 10.39 117 30100 8821 50566086
Clostridium difficile infection 139.27 10.39 118 30099 25321 50549586
Type IV hypersensitivity reaction 123.94 10.39 49 30168 2433 50572474
Dermatitis allergic 104.42 10.39 75 30142 12645 50562262
Rash maculo-papular 90.78 10.39 95 30122 26546 50548361
Rash 89.44 10.39 504 29713 436967 50137940
Symmetrical drug-related intertriginous and flexural exanthema 84.57 10.39 23 30194 339 50574568
Hidradenitis 71.54 10.39 31 30186 1944 50572963
Graft infection 70.67 10.39 17 30200 148 50574759
Toxic skin eruption 69.51 10.39 56 30161 11195 50563712
Drug reaction with eosinophilia and systemic symptoms 67.38 10.39 84 30133 28340 50546567
Urticaria 65.68 10.39 198 30019 129363 50445544
Multiple organ dysfunction syndrome 61.58 10.39 109 30108 50228 50524679
Drug resistance 59.89 10.39 65 30152 18924 50555983
Cellulitis 56.20 10.39 128 30089 70670 50504237
Loss of employment 54.54 10.39 24 30193 1562 50573345
Clostridium difficile colitis 51.24 10.39 58 30159 17684 50557223
Pemphigus 50.94 10.39 6 30211 120160 50454747
Synovitis 50.53 10.39 7 30210 123858 50451049
Abscess 47.02 10.39 50 30167 14222 50560685
Glossodynia 46.05 10.39 7 30210 115562 50459345
Hand deformity 40.08 10.39 6 30211 100193 50474714
Pathogen resistance 38.76 10.39 30 30187 5659 50569248
Tubo-ovarian abscess 37.58 10.39 12 30205 316 50574591
Systemic lupus erythematosus 35.34 10.39 20 30197 140602 50434305
Pneumococcal infection 34.90 10.39 12 30205 400 50574507
Arthropathy 34.87 10.39 26 30191 157880 50417027
Anaphylactic reaction 34.62 10.39 90 30127 53965 50520942
Pseudomembranous colitis 33.92 10.39 21 30196 2764 50572143
Osteonecrosis of jaw 32.98 10.39 65 30152 32461 50542446
Death 32.94 10.39 93 30124 325286 50249621
Upper respiratory tract infection bacterial 32.26 10.39 8 30209 80 50574827
Toxic epidermal necrolysis 31.73 10.39 50 30167 20942 50553965
Type I hypersensitivity 31.66 10.39 19 30198 2366 50572541
Rheumatoid arthritis 31.55 10.39 45 30172 202505 50372402
Diarrhoea 31.42 10.39 509 29708 587967 49986940
Toxic shock syndrome streptococcal 31.16 10.39 8 30209 93 50574814
Abscess neck 30.38 10.39 12 30205 594 50574313
Cholecystitis chronic 30.31 10.39 33 30184 9636 50565271
Premature delivery 29.91 10.39 52 30165 23611 50551296
Anti-cyclic citrullinated peptide antibody positive 28.75 10.39 4 30213 70583 50504324
Joint swelling 27.17 10.39 67 30150 245219 50329688
Peripheral swelling 27.17 10.39 51 30166 205885 50369022
Infusion related reaction 27.07 10.39 37 30180 169520 50405387
Hepatitis infectious mononucleosis 26.99 10.39 7 30210 85 50574822
Injury 26.88 10.39 77 30140 48848 50526059
Mastitis 26.83 10.39 17 30200 2330 50572577
Pericarditis 26.69 10.39 7 30210 78682 50496225
Leukocytosis 26.45 10.39 48 30169 22531 50552376
Skin odour abnormal 25.64 10.39 14 30203 1458 50573449
Klebsiella infection 25.12 10.39 26 30191 7168 50567739
Alopecia 24.07 10.39 71 30146 244976 50329931
Contraindicated product administered 23.28 10.39 33 30184 148925 50425982
Type IIb hyperlipidaemia 22.41 10.39 5 30212 30 50574877
Escherichia infection 22.27 10.39 30 30187 10911 50563996
Necrotising oesophagitis 22.03 10.39 6 30211 89 50574818
Puerperal pyrexia 21.50 10.39 5 30212 37 50574870
Staphylococcal infection 21.48 10.39 58 30159 35558 50539349
Fatigue 21.45 10.39 296 29921 707305 49867602
Sepsis syndrome 20.74 10.39 10 30207 803 50574104
Erythema 20.69 10.39 154 30063 146260 50428647
Pneumothorax 20.62 10.39 33 30184 14001 50560906
Intentional overdose 20.37 10.39 6 30211 62498 50512409
Helicobacter infection 19.81 10.39 3 30214 49699 50525208
Surgical failure 19.56 10.39 10 30207 911 50573996
Musculoskeletal stiffness 19.54 10.39 29 30188 128452 50446455
Wound secretion 19.44 10.39 17 30200 3800 50571107
Blood testosterone increased 19.32 10.39 6 30211 144 50574763
Drug eruption 19.07 10.39 43 30174 23563 50551344
Bronchial obstruction 19.02 10.39 11 30206 1279 50573628
Discomfort 19.01 10.39 22 30195 108358 50466549
Completed suicide 18.89 10.39 31 30186 131858 50443049
Reaction to azo-dyes 18.89 10.39 4 30213 18 50574889
Lower respiratory tract infection bacterial 18.75 10.39 7 30210 297 50574610
Gastric disorder 18.71 10.39 49 30168 29499 50545408
Pyrexia 18.42 10.39 324 29893 379879 50195028
Drug intolerance 18.40 10.39 68 30149 219036 50355871
Injection site erythema 18.33 10.39 11 30206 74925 50499982
Breast abscess 18.22 10.39 11 30206 1384 50573523
Septic shock 18.19 10.39 75 30142 57100 50517807
Hepatic steatosis 18.14 10.39 43 30174 24341 50550566
Acute kidney injury 18.11 10.39 212 30005 227846 50347061
Acinetobacter infection 17.99 10.39 11 30206 1416 50573491
Respiratory gas exchange disorder 17.87 10.39 7 30210 339 50574568
Skin lesion 17.62 10.39 45 30172 26682 50548225
Thyroxine increased 17.57 10.39 8 30209 564 50574343
Antibiotic level below therapeutic 17.40 10.39 4 30213 28 50574879
Weight increased 17.38 10.39 62 30155 201829 50373078
Osteomyelitis 17.26 10.39 40 30177 22313 50552594
Pneumonia necrotising 17.23 10.39 7 30210 373 50574534
Venous haemorrhage 17.20 10.39 6 30211 209 50574698
Drug-induced liver injury 17.19 10.39 46 30171 28049 50546858
Toxicity to various agents 17.16 10.39 67 30150 212432 50362475
Oesophageal ulcer 17.01 10.39 16 30201 3929 50570978
Exposure during pregnancy 16.93 10.39 127 30090 120888 50454019
Hypoglossal nerve paresis 16.64 10.39 5 30212 107 50574800
Dermatitis acneiform 16.63 10.39 16 30201 4041 50570866
Oesophagitis 16.38 10.39 29 30188 13354 50561553
Prothrombin time prolonged 16.14 10.39 23 30194 8815 50566092
Vulval abscess 16.07 10.39 8 30209 689 50574218
Stevens-Johnson syndrome 15.79 10.39 38 30179 21714 50553193
Toxic shock syndrome 15.49 10.39 7 30210 485 50574422
Swelling of eyelid 15.34 10.39 11 30206 1849 50573058
Pruritus 15.31 10.39 246 29971 283322 50291585
Documented hypersensitivity to administered product 15.21 10.39 7 30210 506 50574401
Perihepatic discomfort 15.12 10.39 3 30214 9 50574898
Pseudomonas infection 15.00 10.39 23 30194 9407 50565500
Serratia infection 14.93 10.39 8 30209 802 50574105
Pneumomediastinum 14.82 10.39 9 30208 1144 50573763
Necrosis 14.56 10.39 16 30201 4720 50570187
Deep vein thrombosis 14.55 10.39 84 30133 73220 50501687
Erosive oesophagitis 14.50 10.39 10 30207 1579 50573328
Factor V inhibition 14.42 10.39 5 30212 171 50574736
Coma 14.41 10.39 8 30209 56871 50518036
Clostridium test positive 14.27 10.39 11 30206 2061 50572846
Infected skin ulcer 14.23 10.39 11 30206 2070 50572837
Chronic respiratory disease 14.18 10.39 4 30213 68 50574839
Multi-organ disorder 14.14 10.39 9 30208 1244 50573663
Necrotising fasciitis 14.08 10.39 12 30205 2592 50572315
Hepatic enzyme increased 14.06 10.39 39 30178 137341 50437566
Joint vibration 13.91 10.39 3 30214 15 50574892
Megacolon 13.86 10.39 10 30207 1696 50573211
Tubulointerstitial nephritis 13.76 10.39 29 30188 15182 50559725
Infection protozoal 13.74 10.39 3 30214 16 50574891
Oxygen saturation abnormal 13.69 10.39 12 30205 2690 50572217
Confusional state 13.53 10.39 61 30156 185867 50389040
Chronic kidney disease 13.31 10.39 53 30164 39718 50535189
Wound 13.24 10.39 27 30190 105767 50469140
Product use in unapproved indication 13.19 10.39 116 30101 115703 50459204
Lymphadenopathy 13.17 10.39 47 30170 33452 50541455
Rash morbilliform 13.16 10.39 12 30205 2834 50572073
Babesiosis 13.13 10.39 5 30212 224 50574683
Lemierre syndrome 13.00 10.39 4 30213 93 50574814
Eosinophilia 12.92 10.39 32 30185 18620 50556287
Tooth extraction 12.87 10.39 21 30196 9054 50565853
Emotional distress 12.83 10.39 42 30175 28621 50546286
Hyperleukocytosis 12.73 10.39 6 30211 458 50574449
Acute respiratory failure 12.73 10.39 42 30175 28740 50546167
Abortion spontaneous 12.67 10.39 54 30163 41718 50533189
Geotrichum infection 12.66 10.39 6 30211 464 50574443
Adenocarcinoma 12.54 10.39 11 30206 2470 50572437
Swelling face 12.28 10.39 63 30154 52532 50522375
Vulvovaginal discomfort 12.27 10.39 10 30207 2031 50572876
Mycobacterial infection 12.16 10.39 9 30208 1587 50573320
Bronchopulmonary dysplasia 12.12 10.39 5 30212 277 50574630
Allergy to metals 12.11 10.39 6 30211 511 50574396
Rash erythematous 12.11 10.39 47 30170 34805 50540102
Overdose 12.02 10.39 26 30191 99701 50475206
Haemodynamic instability 11.97 10.39 19 30198 8005 50566902
Fibromyalgia 11.87 10.39 6 30211 44972 50529935
Abdominal sepsis 11.81 10.39 8 30209 1227 50573680
Skin infection 11.78 10.39 24 30193 12267 50562640
Type 2 diabetes mellitus 11.76 10.39 3 30214 34372 50540535
Wound complication 11.57 10.39 11 30206 2739 50572168
Tracheal haemorrhage 11.34 10.39 4 30213 144 50574763
Lower respiratory tract infection 11.33 10.39 25 30192 95176 50479731
Abdominal wall disorder 11.18 10.39 4 30213 150 50574757
Bezoar 11.18 10.39 8 30209 1340 50573567
Abscess jaw 11.12 10.39 8 30209 1350 50573557
Perioral dermatitis 11.11 10.39 4 30213 153 50574754
Bone sequestrum 11.02 10.39 8 30209 1370 50573537
Moraxella infection 11.00 10.39 5 30212 351 50574556
Coagulation factor decreased 10.92 10.39 3 30214 46 50574861
Product use issue 10.90 10.39 49 30168 149426 50425481
Subcutaneous abscess 10.89 10.39 14 30203 4868 50570039
Shock 10.85 10.39 32 30185 20618 50554289
Anhedonia 10.84 10.39 20 30197 9504 50565403
Sphingomonas paucimobilis infection 10.74 10.39 3 30214 49 50574858
Folliculitis 10.71 10.39 5 30212 39220 50535687
Pulmonary embolism 10.63 10.39 100 30117 101604 50473303

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 310.63 12.19 283 17138 68123 29488983
Type IV hypersensitivity reaction 226.58 12.19 64 17357 1110 29555996
Rash maculo-papular 187.25 12.19 137 17284 24152 29532954
Acute generalised exanthematous pustulosis 126.41 12.19 63 17358 5520 29551586
Rash 110.93 12.19 302 17119 189517 29367589
Drug reaction with eosinophilia and systemic symptoms 91.56 12.19 97 17324 27895 29529211
Clostridium difficile colitis 62.36 12.19 56 17365 13156 29543950
Kounis syndrome 61.07 12.19 27 17394 1802 29555304
Drug ineffective 56.01 12.19 385 17036 362785 29194321
Graft infection 47.73 12.19 15 17406 380 29556726
Dermatitis allergic 41.34 12.19 31 17390 5657 29551449
Pseudomembranous colitis 40.88 12.19 23 17398 2574 29554532
Methaemoglobinaemia 40.28 12.19 23 17398 2648 29554458
Death 40.14 12.19 89 17332 341995 29215111
Oesophageal ulcer 39.52 12.19 24 17397 3096 29554010
Drug eruption 36.29 12.19 47 17374 16694 29540412
Cellulitis 36.18 12.19 82 17339 45758 29511348
Surgical failure 33.33 12.19 8 17413 70 29557036
Toxic skin eruption 32.21 12.19 34 17387 9723 29547383
Pruritus 32.04 12.19 145 17276 116704 29440402
Abscess of salivary gland 31.72 12.19 6 17415 13 29557093
Abscess 30.43 12.19 33 17388 9729 29547377
Electrocardiogram U wave present 29.84 12.19 6 17415 20 29557086
Venolymphatic malformation 29.19 12.19 6 17415 23 29557083
Erythema 28.84 12.19 104 17317 75502 29481604
Glomerulosclerosis 28.54 12.19 12 17409 708 29556398
Tubulointerstitial nephritis 28.49 12.19 43 17378 17600 29539506
Resorption bone increased 27.29 12.19 8 17413 159 29556947
Mucormycosis 26.61 12.19 23 17398 5135 29551971
Stevens-Johnson syndrome 26.34 12.19 40 17381 16457 29540649
Overgrowth bacterial 25.42 12.19 7 17414 110 29556996
Hidradenitis 25.01 12.19 11 17410 725 29556381
Megacolon 24.68 12.19 14 17407 1591 29555515
Renal hypoplasia 24.19 12.19 6 17415 61 29557045
Skin graft failure 23.98 12.19 7 17414 137 29556969
Pyrexia 23.69 12.19 266 17155 287356 29269750
Clostridium test positive 23.56 12.19 15 17406 2102 29555004
Calcium deficiency 23.43 12.19 7 17414 149 29556957
Pathogen resistance 22.83 12.19 26 17395 8090 29549016
Osteomyelitis salmonella 22.62 12.19 5 17416 29 29557077
Rash pustular 22.36 12.19 20 17401 4671 29552435
Cutaneous vasculitis 21.96 12.19 17 17404 3251 29553855
Oesophagitis chemical 21.69 12.19 5 17416 36 29557070
Necrotising fasciitis 21.52 12.19 17 17404 3348 29553758
Anamnestic reaction 21.45 12.19 5 17416 38 29557068
Oesophagitis 20.60 12.19 30 17391 11893 29545213
Osteomyelitis 20.15 12.19 32 17389 13677 29543429
Gastrointestinal mucosa hyperaemia 19.78 12.19 7 17414 258 29556848
Rash erythematous 19.77 12.19 41 17380 21521 29535585
Antibiotic level below therapeutic 19.10 12.19 5 17416 64 29557042
Sialoadenitis 18.99 12.19 8 17413 474 29556632
Exophthalmos 18.23 12.19 8 17413 524 29556582
Pneumatosis intestinalis 18.13 12.19 15 17406 3154 29553952
Vitamin A deficiency 18.13 12.19 4 17417 23 29557083
Swelling face 17.85 12.19 38 17383 20312 29536794
Staphylococcal infection 17.43 12.19 47 17374 29193 29527913
Pulmonary venous thrombosis 17.17 12.19 5 17416 97 29557009
Pouchitis 17.15 12.19 8 17413 605 29556501
Drug clearance increased 17.12 12.19 5 17416 98 29557008
Urine alcohol test positive 17.09 12.19 4 17417 31 29557075
Kidney fibrosis 16.78 12.19 12 17409 2035 29555071
Polycystic liver disease 16.77 12.19 4 17417 34 29557072
Anal ulcer 16.61 12.19 8 17413 650 29556456
Post procedural fistula 16.18 12.19 4 17417 40 29557066
Vitamin B1 deficiency 16.10 12.19 6 17415 257 29556849
Drug resistance 15.30 12.19 37 17384 21503 29535603
Folate deficiency 15.20 12.19 9 17412 1108 29555998
Drug-induced liver injury 15.18 12.19 37 17384 21618 29535488
Diarrhoea 15.02 12.19 277 17144 332421 29224685
Leg amputation 14.45 12.19 11 17410 2053 29555053
Laryngitis 14.41 12.19 11 17410 2060 29555046
Urticaria 14.33 12.19 67 17354 54593 29502513
Proctitis 14.19 12.19 11 17410 2108 29554998
Drug ineffective for unapproved indication 14.19 12.19 28 17393 14186 29542920
Arthrofibrosis 14.07 12.19 4 17417 71 29557035
Magnesium deficiency 13.96 12.19 4 17417 73 29557033
Acute kidney injury 13.80 12.19 226 17195 265041 29292065
Dry gangrene 13.79 12.19 6 17415 385 29556721
Fungal infection 13.71 12.19 27 17394 13658 29543448
Intentional overdose 13.64 12.19 3 17418 38525 29518581
Cardiac failure congestive 13.62 12.19 15 17406 76566 29480540
Post infection glomerulonephritis 13.49 12.19 3 17418 18 29557088
Device toxicity 13.35 12.19 3 17418 19 29557087
Toxic shock syndrome streptococcal 13.09 12.19 3 17418 21 29557085
Toxic epidermal necrolysis 12.70 12.19 31 17390 18122 29538984
Cardiac failure 12.55 12.19 17 17404 79270 29477836
Limb fracture 12.32 12.19 3 17418 28 29557078
Gastrointestinal submucosal tumour 12.21 12.19 4 17417 116 29556990
Debridement 12.20 12.19 7 17414 813 29556293

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 474.10 10.60 641 37588 237174 64223329
Type IV hypersensitivity reaction 343.47 10.60 113 38116 3309 64457194
Acute generalised exanthematous pustulosis 327.37 10.60 162 38067 13896 64446607
Rash maculo-papular 275.38 10.60 226 38003 46800 64413703
Rash 184.31 10.60 643 37586 457906 64002597
Drug reaction with eosinophilia and systemic symptoms 155.70 10.60 176 38053 54041 64406462
Graft infection 110.76 10.60 32 38197 599 64459904
Clostridium difficile colitis 104.17 10.60 103 38126 27120 64433383
Toxic skin eruption 99.06 10.60 86 38143 19198 64441305
Abscess 89.04 10.60 81 38148 19223 64441280
Hidradenitis 82.80 10.60 36 38193 2293 64458210
Clostridium difficile infection 81.78 10.60 104 38125 36059 64424444
Cellulitis 77.07 10.60 171 38058 93486 64367017
Drug resistance 71.68 10.60 96 38133 35006 64425497
Drug ineffective 69.03 10.60 780 37449 839467 63621036
Symmetrical drug-related intertriginous and flexural exanthema 68.37 10.60 22 38207 599 64459904
Drug abuse 65.74 10.60 3 38226 132371 64328132
Pseudomembranous colitis 62.52 10.60 38 38191 4878 64455625
Oesophageal ulcer 56.76 10.60 39 38190 6171 64454332
Death 54.68 10.60 129 38100 482576 63977927
Pathogen resistance 54.67 10.60 51 38178 12492 64448011
Loss of employment 50.47 10.60 24 38205 1883 64458620
Pyrexia 50.01 10.60 528 37701 558116 63902387
Urticaria 49.95 10.60 196 38033 147121 64313382
Drug eruption 48.21 10.60 81 38148 36055 64424448
Kounis syndrome 48.03 10.60 27 38202 2998 64457505
Surgical failure 47.96 10.60 18 38211 781 64459722
Multiple organ dysfunction syndrome 44.67 10.60 147 38082 101266 64359237
Tubulointerstitial nephritis 43.54 10.60 71 38158 30838 64429665
Stevens-Johnson syndrome 43.36 10.60 75 38154 34174 64426329
Methaemoglobinaemia 41.38 10.60 28 38201 4320 64456183
Staphylococcal infection 41.07 10.60 92 38137 50586 64409917
Erythema 39.73 10.60 217 38012 186853 64273650
Leukocytosis 39.36 10.60 76 38153 37664 64422839
Synovitis 39.08 10.60 6 38223 99084 64361419
Antibiotic level below therapeutic 38.38 10.60 9 38220 70 64460433
Clostridium test positive 37.98 10.60 26 38203 4089 64456414
Toxic epidermal necrolysis 37.73 10.60 74 38155 37092 64423411
Pruritus 37.22 10.60 314 37915 312086 64148417
Type I hypersensitivity 36.38 10.60 24 38205 3550 64456953
Drug-induced liver injury 35.85 10.60 84 38145 47559 64412944
Rash erythematous 34.71 10.60 84 38145 48549 64411954
Megacolon 34.58 10.60 22 38207 3060 64457443
Oesophagitis 33.65 10.60 52 38177 21578 64438925
Joint swelling 32.79 10.60 48 38181 215334 64245169
Mucormycosis 32.28 10.60 30 38199 7311 64453192
Rheumatoid arthritis 30.95 10.60 31 38198 164263 64296240
Diarrhoea 30.93 10.60 600 37629 722104 63738399
Completed suicide 30.42 10.60 54 38175 224360 64236143
Tubo-ovarian abscess 30.28 10.60 10 38219 296 64460207
Abscess neck 30.10 10.60 14 38215 1045 64459458
Mastitis 29.83 10.60 17 38212 1937 64458566
Toxicity to various agents 29.67 10.60 113 38116 363400 64097103
Hepatitis infectious mononucleosis 28.92 10.60 8 38221 127 64460376
Abscess of salivary gland 28.75 10.60 6 38223 25 64460478
Escherichia infection 28.71 10.60 40 38189 15128 64445375
Intentional overdose 28.33 10.60 9 38220 89935 64370568
Rash pustular 28.20 10.60 32 38197 9853 64450650
Cholecystitis chronic 28.09 10.60 31 38198 9256 64451247
Pneumococcal infection 26.95 10.60 12 38217 809 64459694
Premature delivery 26.58 10.60 43 38186 18546 64441957
Toxic shock syndrome streptococcal 26.39 10.60 7 38222 94 64460409
Coma 25.48 10.60 10 38219 87605 64372898
Glomerulosclerosis 25.10 10.60 12 38217 953 64459550
Pseudomonas infection 25.08 10.60 41 38188 17842 64442661
Overdose 24.83 10.60 35 38194 159531 64300972
Swelling face 24.48 10.60 84 38145 59082 64401421
Sialoadenitis 24.37 10.60 14 38215 1619 64458884
Pericarditis 24.16 10.60 4 38225 62512 64397991
Necrotising fasciitis 23.87 10.60 22 38207 5304 64455199
Overgrowth bacterial 23.52 10.60 7 38222 146 64460357
Anaphylactic reaction 22.96 10.60 91 38138 68573 64391930
Septic shock 22.83 10.60 123 38106 105314 64355189
Drug ineffective for unapproved indication 22.45 10.60 54 38175 31079 64429424
Type IIb hyperlipidaemia 22.45 10.60 5 38224 30 64460473
Hand deformity 22.18 10.60 5 38224 62766 64397737
Klebsiella infection 22.18 10.60 33 38196 13248 64447255
Anamnestic reaction 22.17 10.60 5 38224 32 64460471
Puerperal pyrexia 21.91 10.60 5 38224 34 64460469
Osteomyelitis 21.14 10.60 49 38180 27538 64432965
Pemphigus 21.12 10.60 5 38224 60696 64399807
Osteomyelitis salmonella 20.87 10.60 5 38224 43 64460460
Skin graft failure 20.83 10.60 7 38222 219 64460284
Electrocardiogram U wave present 20.58 10.60 6 38223 116 64460387
Reaction to azo-dyes 20.19 10.60 4 38225 12 64460491
Toxic shock syndrome 19.99 10.60 10 38219 876 64459627
Anti-cyclic citrullinated peptide antibody positive 19.54 10.60 3 38226 49559 64410944
Acute kidney injury 19.49 10.60 374 37855 448866 64011637
Arthropathy 19.35 10.60 26 38203 120941 64339562
Fungal infection 19.15 10.60 54 38175 34197 64426306
Rash morbilliform 18.83 10.60 19 38210 5122 64455381
Wound secretion 18.55 10.60 19 38210 5213 64455290
Cholestatic liver injury 18.07 10.60 16 38213 3663 64456840
Ophthalmoplegia 17.96 10.60 14 38215 2688 64457815
Breast abscess 17.85 10.60 10 38219 1103 64459400
Glossodynia 17.82 10.60 8 38221 64688 64395815
Urine alcohol test positive 17.82 10.60 4 38225 25 64460478
Vulval abscess 16.99 10.60 8 38221 614 64459889
Drug intolerance 16.94 10.60 56 38173 187936 64272567
Osteonecrosis of jaw 16.87 10.60 57 38172 39768 64420735
Infected skin ulcer 16.75 10.60 14 38215 2966 64457537
Acute respiratory distress syndrome 16.74 10.60 56 38173 38879 64421624
Pulmonary venous thrombosis 16.63 10.60 5 38224 108 64460395
Post procedural fistula 16.59 10.60 6 38223 234 64460269
Skin infection 16.56 10.60 31 38198 15006 64445497
Hypoglossal nerve paresis 16.55 10.60 5 38224 110 64460393
Gastrointestinal mucosa hyperaemia 16.54 10.60 7 38222 417 64460086
Sepsis syndrome 16.54 10.60 10 38219 1271 64459232
Thyroxine increased 16.44 10.60 8 38221 660 64459843
Acute hepatic failure 16.43 10.60 43 38186 26069 64434434
Peripheral swelling 16.41 10.60 66 38163 209087 64251416
Suicide attempt 16.34 10.60 11 38218 70996 64389507
Postoperative wound infection 16.29 10.60 25 38204 10311 64450192
Injection site erythema 16.25 10.60 11 38218 70789 64389714
Erosive oesophagitis 16.24 10.60 13 38216 2593 64457910
Odynophagia 16.16 10.60 24 38205 9617 64450886
Proctitis 16.04 10.60 14 38215 3145 64457358
Confusional state 16.04 10.60 90 38139 261054 64199449
Venous haemorrhage 15.99 10.60 6 38223 260 64460243
Erysipelas 15.79 10.60 23 38206 9058 64451445
Weight increased 15.70 10.60 69 38160 213279 64247224
Acute febrile neutrophilic dermatosis 15.41 10.60 14 38215 3315 64457188
Eye swelling 15.38 10.60 38 38191 22243 64438260
Skin odour abnormal 15.37 10.60 11 38218 1856 64458647
Clostridial infection 15.33 10.60 17 38212 5102 64455401
Skin lesion 15.26 10.60 52 38177 36430 64424073
Scar 15.23 10.60 28 38201 13370 64447133
Candida infection 15.15 10.60 47 38182 31372 64429131
Perihepatic discomfort 15.14 10.60 3 38226 9 64460494
Bronchial obstruction 15.13 10.60 12 38217 2362 64458141
Leg amputation 15.06 10.60 14 38215 3413 64457090
Fatigue 15.02 10.60 334 37895 748396 63712107
Oesophagitis chemical 14.99 10.60 4 38225 55 64460448
Somnolence 14.90 10.60 66 38163 203579 64256924
Resorption bone increased 14.78 10.60 9 38220 1159 64459344
Aspergillus infection 14.71 10.60 31 38198 16348 64444155
Skin exfoliation 14.61 10.60 59 38170 44826 64415677
Vitamin A deficiency 14.55 10.60 4 38225 62 64460441
Clostridium colitis 14.48 10.60 12 38217 2513 64457990
Prothrombin time prolonged 14.38 10.60 30 38199 15711 64444792
Scedosporium infection 14.19 10.60 9 38220 1245 64459258
Dermatitis acneiform 14.13 10.60 21 38208 8422 64452081
Dermatitis allergic 14.04 10.60 29 38200 15080 64445423
Joint vibration 13.93 10.60 3 38226 15 64460488
Swelling of eyelid 13.80 10.60 11 38218 2181 64458322
Helicobacter infection 13.67 10.60 3 38226 38359 64422144
Cutaneous vasculitis 13.66 10.60 18 38211 6455 64454048
Infection protozoal 13.47 10.60 3 38226 18 64460485
Lower respiratory tract infection bacterial 13.44 10.60 7 38222 667 64459836
Polycystic liver disease 13.37 10.60 4 38225 85 64460418
Lymphadenopathy 13.36 10.60 59 38170 46627 64413876
Device toxicity 13.33 10.60 3 38226 19 64460484
Post infection glomerulonephritis 13.33 10.60 3 38226 19 64460484
Haemorrhagic vasculitis 13.28 10.60 4 38225 87 64460416
Eosinophilia 13.16 10.60 51 38178 38025 64422478
Normochromic anaemia 13.05 10.60 6 38223 436 64460067
Sensory disturbance 13.04 10.60 26 38203 13182 64447321
Drug clearance increased 13.02 10.60 5 38224 231 64460272
Skin oedema 13.01 10.60 9 38220 1439 64459064
Lip swelling 12.93 10.60 45 38184 31862 64428641
Calcium deficiency 12.85 10.60 7 38222 731 64459772
Acinetobacter infection 12.81 10.60 11 38218 2418 64458085
Abscess limb 12.80 10.60 17 38212 6144 64454359
Serratia infection 12.65 10.60 9 38220 1504 64458999
Anal ulcer 12.65 10.60 8 38221 1101 64459402
Respiratory gas exchange disorder 12.61 10.60 7 38222 758 64459745
Product use in unapproved indication 12.60 10.60 160 38069 176458 64284045
Injury 12.58 10.60 66 38163 55926 64404577
Rash pruritic 12.44 10.60 67 38162 57337 64403166
Vulvovaginal discomfort 12.43 10.60 9 38220 1546 64458957
Exophthalmos 12.41 10.60 9 38220 1551 64458952
Kidney fibrosis 12.35 10.60 12 38217 3089 64457414
Intracranial mass 12.32 10.60 10 38219 2033 64458470
Upper respiratory tract infection bacterial 12.32 10.60 4 38225 112 64460391
Arthrofibrosis 12.26 10.60 4 38225 114 64460389
Lemierre syndrome 12.22 10.60 4 38225 115 64460388
Pouchitis 12.13 10.60 7 38222 817 64459686
Systemic lupus erythematosus 12.09 10.60 17 38212 77595 64382908
Idiosyncratic drug reaction 12.08 10.60 8 38221 1191 64459312
Babesiosis 12.07 10.60 5 38224 282 64460221
Angioedema 11.97 10.60 70 38159 61751 64398752
Gastrointestinal submucosal tumour 11.97 10.60 4 38225 123 64460380
Rash macular 11.95 10.60 36 38193 23649 64436854
Liver injury 11.94 10.60 42 38187 29890 64430613
Documented hypersensitivity to administered product 11.94 10.60 7 38222 841 64459662
Muscle necrosis 11.94 10.60 8 38221 1215 64459288
Candida osteomyelitis 11.86 10.60 3 38226 33 64460470
Limb fracture 11.78 10.60 3 38226 34 64460469
Pneumatosis intestinalis 11.75 10.60 15 38214 5214 64455289
Hypoglobulinaemia 11.62 10.60 3 38226 36 64460467
Sedation 11.62 10.60 5 38224 41457 64419046
Infusion related reaction 11.61 10.60 54 38175 164413 64296090
Hypersensitivity vasculitis 11.58 10.60 17 38212 6744 64453759
Vitamin B1 deficiency 11.50 10.60 6 38223 574 64459929
Tremor 11.48 10.60 47 38182 148183 64312320
Pneumonia necrotising 11.39 10.60 7 38222 916 64459587
Accidental overdose 11.22 10.60 3 38226 33554 64426949
Medication error 11.15 10.60 8 38221 49958 64410545
Cerebral toxoplasmosis 11.15 10.60 9 38220 1817 64458686
Pharyngeal abscess 11.07 10.60 6 38223 620 64459883
Gastrointestinal bacterial overgrowth 11.07 10.60 5 38224 349 64460154
Factor V inhibition 11.02 10.60 5 38224 352 64460151
Coagulation factor decreased 10.99 10.60 4 38225 159 64460344
Oxygen saturation abnormal 10.94 10.60 12 38217 3559 64456944
Headache 10.93 10.60 235 37994 529232 63931271
Tooth extraction 10.83 10.60 20 38209 9581 64450922
Gastric disorder 10.83 10.60 40 38189 29157 64431346
Insomnia 10.67 10.60 71 38158 197765 64262738

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0515779 Lincosamides
FDA PE N0000009982 Decreased Sebaceous Gland Activity
FDA EPC N0000175443 Lincosamide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
FDA PE N0000175731 Neuromuscular Blockade

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Anaerobic septicemia indication 1976008
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Pneumonia due to Streptococcus indication 34020007
Empyema of pleura indication 58554001 DOID:3798
Acne vulgaris indication 88616000
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Infectious disease of abdomen indication 128070006
Pneumococcal pneumonia indication 233607000
Gas gangrene caused by clostridium perfringens indication 266093005
Streptococcus pyogenes infection indication 302809008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Aspiration pneumonia indication 422588002 DOID:3240
Infection due to anaerobic bacteria indication 423451008
Osteomyelitis due to Staphylococcus aureus indication 428783003
Skin and Skin Structure Anaerobic Infection indication
Anaerobic Tubo-Ovarian Abscess indication
Prevention of Bacterial Endocarditis indication
Anaerobic Lung Abscess indication
Anaerobic Endometritis indication
Clostridium Perfringens Empyema indication
Anaerobic Peritonitis indication
Anaerobic Joint Infection indication
Anaerobic Pelvic Cellulitis indication
Intra-Abdominal Anaerobic Abscess indication
Inflammatory Disease of Female Pelvic Organs indication
Pyrexia of unknown origin off-label use 7520000
Inhalational anthrax off-label use 11389007
Actinomycotic infection off-label use 11817007 DOID:8478
Babesiosis off-label use 21061004 DOID:9643
Sinusitis off-label use 36971009
Erysipelas off-label use 44653001 DOID:11330
Malaria off-label use 61462000 DOID:12365
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Bacterial infection of skin off-label use 128936008
Toxoplasmosis off-label use 187192000 DOID:9965
Diverticulitis of gastrointestinal tract off-label use 271366000
Infective otitis media off-label use 312218008
Rosacea off-label use 398909004 DOID:8881
Pneumocystosis jiroveci pneumonia off-label use 415125002 DOID:11339
Toxoplasmosis associated with acquired immunodeficiency syndrome off-label use 421666009
Chloroquine Resistant Plasmodium Falciparum Malaria off-label use
Diabetic Foot Infection off-label use
Encephalitis due to Toxoplasmosis off-label use
Atopic dermatitis contraindication 24079001 DOID:3310
Crohn's disease contraindication 34000006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Ulcerative colitis contraindication 64766004 DOID:8577
Pseudomembranous enterocolitis contraindication 397683000
Bloody Stools contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.46 acidic
pKa2 6.51 acidic
pKa3 12.55 acidic
pKa4 13.71 acidic
pKa5 7.52 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2% BASE CLINDESSE PADAGIS US N050793 Nov. 30, 2004 RX CREAM VAGINAL 6899890 April 27, 2023 METHOD OF TREATING BACTERIAL VAGINOSIS
1% EVOCLIN MYLAN N050801 Oct. 22, 2004 RX AEROSOL, FOAM TOPICAL 7374747 Jan. 23, 2024 TREATMENT OF ACNE VULGARIS
EQ 2% BASE CLINDESSE PADAGIS US N050793 Nov. 30, 2004 RX CREAM VAGINAL 9789057 Dec. 2, 2026 METHOD OF TREATING BACTERIAL VAGINOSIS
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 10220049 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 10624918 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8663699 June 3, 2029 TREATMENT OF ACNE
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8895070 June 3, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 10137142 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 10220049 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9561208 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TOPICAL TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE VULGARIS
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL 11129896 Sept. 22, 2036 METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1.2%;0.025% CLINDAMYCIN PHOSPHATE AND TRETINOIN SOLARIS PHARMA CORP A212845 Feb. 10, 2022 RX GEL TOPICAL Oct. 9, 2022 COMPETITIVE GENERIC THERAPY
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL Dec. 7, 2024 NEW PRODUCT
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL Dec. 7, 2029 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

None

External reference:

IDSource
4018084 VUID
N0000179085 NUI
D01073 KEGG_DRUG
4018084 VANDF
4019683 VANDF
C0055881 UMLSCUI
CHEBI:3746 CHEBI
CHEBI:3745 CHEBI
CLY PDB_CHEM_ID
CHEMBL3184512 ChEMBL_ID
C007084 MESH_SUPPLEMENTAL_RECORD_UI
EH6D7113I8 UNII
443385 PUBCHEM_CID
446598 PUBCHEM_CID
DB01190 DRUGBANK_ID
2582 RXNORM
29382 MMSL
3963 MMSL
41731 MMSL
4466 MMSL
4469 MMSL
4813 MMSL
d00043 MMSL
002794 NDDF
002796 NDDF
372786004 SNOMEDCT_US
37648000 SNOMEDCT_US
58883005 SNOMEDCT_US
C0008947 UMLSCUI
2550 INN_ID
D002981 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0302 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0602 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0728 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0775 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0870 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0901 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0902 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3051 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 27 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3116 SOLUTION 10 mg TOPICAL NDA 23 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3124 INJECTION, SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3329 LOTION 10 mg TOPICAL NDA 23 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3331 GEL 10 mg TOPICAL NDA 23 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3375 INJECTION, SOLUTION 12 mg INTRAVENOUS NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3381 INJECTION, SOLUTION 6 mg INTRAVENOUS NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3382 INJECTION, SOLUTION 18 mg INTRAVENOUS NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3447 INJECTION, SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Cleocin HUMAN PRESCRIPTION DRUG LABEL 1 0009-3448 CREAM 20 mg VAGINAL NDA 25 sections
Cleocin HUMAN PRESCRIPTION DRUG LABEL 1 0009-3448 CREAM 20 mg VAGINAL NDA 25 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3470 INJECTION, SOLUTION 6 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-4073 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 27 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-5095 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 27 sections
CLEOCIN PHOSPHATE (0009-6582) (STANDALONE) HUMAN PRESCRIPTION DRUG LABEL 1 0009-6582 INJECTION, SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-6780 INJECTION, SOLUTION 12 mg INTRAMUSCULAR NDA 26 sections
Cleocin HUMAN PRESCRIPTION DRUG LABEL 1 0009-7667 SUPPOSITORY 100 mg VAGINAL NDA 24 sections
Cleocin HUMAN PRESCRIPTION DRUG LABEL 1 0009-7667 SUPPOSITORY 100 mg VAGINAL NDA 24 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-9890 INJECTION, SOLUTION 18 mg INTRAMUSCULAR NDA 26 sections
clindamycin phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0201 SOLUTION 10 mg TOPICAL ANDA 18 sections
clindamycin phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0201 SOLUTION 10 mg TOPICAL ANDA 18 sections
clindamycin phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0202 GEL 10 mg TOPICAL ANDA 18 sections
clindamycin phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0202 GEL 10 mg TOPICAL ANDA 18 sections